Since the discovery two decades ago that programmable endonucleases can be engineered to modify human cells at single nucleotide resolution, the concept of genome editing was born. Now these technologies are being applied to therapeutically relevant cell types, including hematopoietic stem cells (HSC), which possess the power to repopulate an entire blood and immune system. The purpose of this review is to discuss the changing landscape of genome editing in hematopoietic stem cells (GE-HSC) from the discovery stage to the preclinical stage, with the imminent goal of clinical translation for the treatment of serious genetic diseases of the blood and immune system.
INTRODUCTION
Allogeneic bone marrow transplants [now known as allo-hematopoietic stem cell (HSC) transplants (allo-HSCT)] have been used since the late 1960s to offer a potential lifetime cure for a variety of monogenic hematological diseases, notably the primary immunodeficiencies [1] and b-hemoglobinopathies [2, 3] . Now, the CD34 þ cell surface marker is used to identify a very heterogeneous population of human cells commonly referred to as hematopoietic stem and progenitor cells (HSPCs), which includes a small fraction of bona fide long-term repopulating HSCs. Once physical niche space has been created following myeloablative conditioning regiments, HSPCs have the ability to repopulate an entire hematopoietic system for more than 10 years of the patient's life (and theoretically the entire life of the patient). The key feature is that whenever allo-HSCT is successful, the patient is cured for life, highlighting the concept that transplantation of HSCs that contain a nondisease causing variant of a gene can produce a functional blood and immune system. Although allo-HSCT can cure multiple genetic diseases of the blood and immune systems, the challenge of finding an HLA immunologic matched donor and the subsequent immune complications of Graft versus Host Disease (GvHD) and incomplete immune reconstitution remain.
In disease-specific cases wherever there are no suitable HLA-matched bone marrow donors, autologous HSPCs have been treated with integrating viral vectors that carry the defective gene and then reinfused back into the patient, and whereas this has shown to work for diseases like ADA-SCID [4] and even more recently for SCD [5] , viral vector-based gene therapies carry the risk of insertional mutagenesis [6] . Now with state-of-the-art programmable nucleases technologies available to researchers alike, we believe that an even more promising, and collectively safer approach, would be autologous transplantation with the patient's own HSCs that have been gene-edited ex vivo to confer an indicationspecific therapeutic benefit (Fig. 1) . Here we review the current state of HSC-based therapeutic gene editing using engineered nucleases and discuss where we see the field heading in the future and what barriers remain for clinical translation.
STATE-OF-THE-ART GENOME EDITING REAGENTS FOR HEMATOPOIETIC STEM CELLS ARE NECESSARY FOR CLINICAL TRANSLATION
The introduction of genome editing using engineered nucleases has transformed the idea that gene therapy for monogenetic diseases is attainable; but to be able to translate HSC-based genome-editing technologies to the clinic, it is critical to have genome-editing reagents that are efficient, specific, scalable and nontoxic. Towards this end, there have been important improvements in classes of programmable nucleases, nuclease delivery and homologous donor template delivery.
Genome editing is the process where a sitespecific double-strand break (DSB) is created using engineered nucleases that subsequently triggers the cell's endogenous repair machinery to modify (or edit) the genome in a site-specific manner. Currently there are five major classes of engineered nucleases used in genome editing (listed in chronological order of discovery: homing endonucleases, zinc finger nucleases (ZFNs), transcription-activator-like effector nucleases (TALENs), megaTALs and more recently the RNA-programmable (sgRNA) clustered regularly interspace short palindromic repeats (CRISPR)-Cas9 nuclease (Cas9/sgRNA) system [7] . Although each nuclease platform is at different stages of clinical development (Table 1) , the Cas9/sgRNA system, because of its specificity, ease of design, scalability of raw materials and high efficiencies, is poised to be the engineered nuclease of choice for genome-editing clinical therapies.
The Cas9/sgRNA system consists of the Cas9 endonuclease and a $100-nucleotide single guide RNA (gRNA). The most commonly used Cas9/gRNA system is derived from Streptococcus pyogenes (SpCas9) and we briefly describe the SpCas9 system as follows. Target identification relies first on identification of a 3-base pair protospacer adjacent motif (PAM) and then base-pairing between a 20-nucleotide stretch of the gRNA and the DNA target site, which triggers Cas9 to cleave both DNA strands. Although the Cas9/gRNA system was shown to work in human HSPCs and a clever dual guide approach improved editing outcomes, the efficiencies were still likely too low for clinical translation [8] . Until recently when Hendel et al. [9] , showed that sgRNAs modified at both termini with 2 0 O-methyl 3 0 phosphorothioate dramatically enhanced genomeediting efficiencies in primary HSPCs. Another major advancement was the delivery method of the Cas9/ sgRNA system into HSPCs from plasmid-based [8] to RNA-based [9] to more recently, as precomplexed ribonucleoproteins (RNPs) [10 & ]. We believe that the most effective method and best for clinical applications is RNP delivery as it maintains high activity (hit), while reducing duration of nuclease exposure (and-run); thus using a hit-and-run mechanism. Importantly, it also reduces the stimulation of innate immunity signaling that recognizes naked DNA and RNA, which
KEY POINTS
Gene editing of hematopoietic stem cells (GE-HSC) holds tremendous promise for the development of novel blood and immune system cell and gene therapies. Therapeutic GE-HSC by NHEJ can knockout a gene (CCR5 or BCL11A) or disrupt the enhancer of a repressive transcription factor (BCL11A) to increase gene expression, both will result in a disease-specific therapeutic benefit. Therapeutic GE-HSC by homologous recombination can be used to correct disease-causing nucleotide substitutions, functional gene correction as well as targeted transgene addition into 'safe harbor' sites in the genome (like AAVS1) to elicit a therapeutic benefit.
Although homologous recombination has been shown to be more refractory in HSCs compared with NHEJ, recent robust selection methods have been reported to circumvent this problem.
Future preclinical research must focus on the long-term safety and tumorigenic potential of the GE-HSC therapeutic cell candidates.
can lead to increased toxicity and reduced editing outcomes in stem cells.
Once an engineered nuclease creates a site-specific DNA double-strand break for genome editing, the cell activates the double-strand break repair (DSBR) machinery to fix the break. There are multiple DSBR pathways but the main canonical mechanisms are nonhomologous end-joining (NHEJ) and homologous recombination (Fig. 1) . NHEJ repair is the pathway that functions throughout the cell cycle to correct breaks through ligation of DNA ends. While usually precise in the joining of ends that is created by an engineered nuclease, through the iterative cycle of break and NHEJ-mediated repair, insertions and/or deletions (INDELs), can be created at the site of the break. By creating site-specific INDELs, genetic elements, such as enhancers, TAD domains, microRNAs and coding regions of genes can be disrupted. þ HSPCs are prestimulated in stem cell cytokine media to promote viability, stemness and cell cycle entry. Fourth, stimulated HSPCs are then subjected to site-specific engineered nuclease-mediated double-strand breaks (DSBs), which can be repaired by nonhomologous end joining (NHEJ), which results in small insertions or deletions that can reactivate or silence gene expression or homologous recombination if a homologous donor is added (ssODN/IDLV/ AAV6), which can be used to correct point mutations or functional gene correction. Fifth, once the gene-edited hematopoietic stem cells (GE-HSC) have been released using stringent potency, efficacy and toxicity endpoints, the patient is then conditioned using myeloablative regiments, such as busulfan, to clear nonedited resident bone-marrow HSCs. Sixth, following myeloablative conditioning to clear the bone marrow stem cell niche, GE-HSC are reinfused into the patient. Lastly, patients are monitored closely for tri-lineage engraftment, pharmacological effect, clinical adverse responses and reduction in symptomology for 24 months, in addition to the FDA requirement of a 15-year follow-up (followed on a yearly basis).
If the cell uses homologous recombination to repair a DSB using an exogenous DNA donor template with arms of homology to the target site, then specific changes in the DNA can be introduced. Since the first report of engineered nucleasestimulated homologous recombination in HSPCs, albeit at very low frequencies [11] , there have been several homologous donor platforms that have been used to stimulate homologous recombination in human HSPCs ( [12, 17] , and more recently, recombinant adeno-associated virus serotype 6 (rAAV6) [18, 19, 20 
Although all of these donors are generally classified as 'Homology Directed Repair', a more precise classification would identify rAAV6 and IDLV donors under homologous recombination-mediated editing because it is a Rad51-dependent process and ssODNs under 'Single-stranded template repair (SSTR)' because it is a Rad51 independent process. That is, genome editing using IDLV or rAAV6 is mechanistically distinct from genome editing using ssODNs and thus should be distinguished from each other whenever assessing different approaches to genome editing. Although current literature may suggest that rAAV6 is a better donor template than IDLV [22] and a more versatile donor than ssODNs because it can mediate precise nucleotide changes as well as insert gene cassettes up to 5.7 kb using a dual-AAV6 platform (Bak and Porteus, in press) [23] , a more comprehensive comparison is needed to compare all donor platforms in a head-to-head fashion. Nevertheless, GE-HSC through homologous recombination could be harnessed to restore gene function in downstream hematopoietic cell lineages for therapeutic purposes. Hendel et al. [9] and Dever et al. [20 && ] both demonstrated that an important feature of genome editing is that whenever high amounts of donor can be delivered to the nucleus without inducing cellular toxicity, the frequency of homologous recombination-mediated editing can exceed the frequency of NHEJ-mediated editing in both cell lines and primary human CD34 
NONHOMOLOGOUS END JOINING-BASED THERAPEUTIC GENOME EDITING STRATEGIES TO REACTIVATE FETAL HEMOGLOBIN FOR THE TREATMENT OF b-HEMOGLOBINOPATHIES
The b-hemoglobinopathies are inherited monogenic blood disorders that result from mutations in the b-globin gene (HBB) and either affect hemoglobin protein production (thalassemia) or hemoglobin tetramer function (sickle cell disease). Sickle cell disease (SCD) is an autosomal recessive disease The different donor platforms to achieve homologous recombination in human HSPCs are outlined in the table. The table summarizes: when the donors were first reported to achieve homologous recombination in HSPCs; the genes targeted using each donor; relative in-vitro efficiencies before transplant into NSG mice (as a readout of stem and progenitor cell targeting rates); relative in-vivo efficiencies following long-term reconstitutions in immunodeficient mice (as a readout of stem cell targeting rates); the versatility of the donor template (is the donor large enough to insert large gene cassettes as well as make single nucleotide changes) and the relative toxicities in HSPCs. AAV6, recombinant adeno-associated virus serotype six; IDLV, integrase-defective lentivirus; ssODN, single-stranded oligodeoxynucleotide. caused by an adenine to thymidine transversion in codon 6 of the HBB gene on chromosome 11 that results in an amino acid change from a polar residue, glutamic acid (E), to a hydrophobic one, valine (V) [24] . Under low-oxygen conditions, the E6V sickle hemoglobin polypeptide (HbS) promotes polymerization with another hemoglobin tetramer and ultimately causes the sickle shape (and thus its name). Fetal hemoglobin (HbF) induction using small molecules, such as hydroxyurea, can ameliorate the severity of both SCD and b-thalassemia patients wherever fetal hemoglobin is normally silenced in adulthood [25] . Building upon this knowledge, Bauer et al. [26] used genome-wide association studies to identify common genetic variation in regulatory regions of a transcriptional repressor, BCL11A, that positively associated with HbF protein expression. Canver et al. [27] , then tightly mapped the critical sequences within the BCL11A enhancer to identify a motif that contained a well known erythroid-specific transcription factor, GATA1, which is thought to be involved during fetal-to-adult hemoglobin switching in humans. Knockdown of BCL11A or deletion of the enhancer region represented a promising strategy to induce HbF in autologous HSPCs for the treatment of SCD.
To this end, Bjurstom et al. [28] , examined whether genome editing of BCL11A exon 2 in HSPCs using ZFNs, TALENs or Cas9/sgRNA could increase HbF. Whereas they observed induction of HbF in vitro, the frequencies were likely too low after engraftment in NSG (4%) to be of therapeutic benefit and on top of that, plasmid delivery of the Cas9/ sgRNA system resulted in very high toxicities, highlighting the importance of nuclease delivery via RNPs as discussed earlier. Because BCL11A is essential for lymphoid development and may be a risky therapeutic target [29] , Tan et al., compared genome editing of BCL11A exon 2 and the GATAA enhancer motif. Using ZFNs, researchers discovered that both strategies resulted in the increase in HbF but not surprisingly, HSPCs that were treated with ZFNs targeting the BCL11A exon 2 displayed significantly reduced engraftment compared editing of the GATAA enhancer, likely because of residual BCL11A expression remaining whenever targeting the enhancer [30] . We believe that these studies highlight the need for more preclinical studies to fine-tune BCL11A expression as early evidence indicates that dramatic loss of BCL11A expression in HSPCs negatively influences hematopoiesis.
Hereditary persistence of fetal hemoglobin (HPFH) is a benign genetic condition where individuals display an unusually high expression of HbF and interestingly, co-inheritance of HPFH in b-thalassemia or SCD patients usually results in the amelioration of clinical symptoms [31, 32] ] used a single guide RNA approach to mutate a 13-nucleotide sequence that is located in the promoters of the two genes that are responsible for HbF expression, HBG1 and HBG2, to recreate a naturally occurring HPFH mutation. Using this approach in healthy CD34
þ HSPCs, the number of HbF expressing differentiated RBCs rose from 18 to 58%. Whenever they employed this strategy in SCD-derived HSPCs and then differentiated edited CD34 þ cells into RBCs, they showed robust rescue of the sickling phenotype found under hypoxic conditions. Although this study is extremely encouraging, the Cas9/sgRNA system was delivered as a lentivirus, which is not therapeutically applicable. It will be interesting to see efficiencies whenever the Cas9/sgRNA components are delivered as an RNP. Importantly though, both studies failed to show engraftment efficiencies and multilineage reconstitution potential of edited HSPCs as well as the genome-editing frequencies in the bone marrow following long-term transplantation. Nevertheless, the strategy of recreating HPFH by genome editing in HSPCs is an interesting and promising viable therapeutic option for treating SCD in the future because it does not depend on harnessing the homologous recombination machinery in HSCs and recapitulates the genetic variants that human genetics has shown to be safe and effective.
HOMOLOGOUS RECOMBINATION-BASED THERAPEUTIC GENOME EDITING TO CORRECT HBB GENE MUTATIONS FOR THE TREATMENT OF b-HEMOGLOBINOPATHIES
Oliver smithies and colleagues first showed in 1985 that homologous recombination could be used to insert DNA sequences into the human HBB locus, albeit at very low frequencies (10 À6 ), but this seminal work planted the seed that homologous recombination-based therapies could be a viable therapeutic option in the future. Since engineered nucleases stimulate homologous recombination as much as 10 000 fold [35] , it was the logical next step
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Along those lines, Hoban et al., used ZFNs to target the HBB locus for a DSB while supplying either an ssODN or IDLV homologous donor vector to change the SCD-causing E6V substitution back to wildtype. Although they observed homologous recombination frequencies above 10% in vitro (10.5% for IDLV and 17.9% for ssODNs), there was a greater than 20-fold drop in homologous recombination efficiencies whenever analyzing human cells in the bone marrow of NSG 16-weeks posttransplant (0.21% for IDLV and 0.85% for ssODNs) [12] . Although these frequencies are obviously too low for therapeutic applications, this important article highlighted the problem with targeting long-term repopulating HSCs for homologous recombination at the HBB locus. The same researchers were the first to show that the Cas9/sgRNA system could also be used to edit the HBB gene by homologous recombination at the E6V position, albeit only showing in-vitro efficiencies in HSPCs up to 18% [14] . Soon after, Dewitt et al. published very promising data showing that by combining HBB-specific Cas9 RNPs and an ssODN intended to modify the E6V region, they could achieve a mean homologous recombination frequency of 12% (and up to 30%) in vitro in mobilized peripheral blood-derived HSPCs. After transplantation into NSG mice, they achieved an average of 2% in long-term repopulating HSCs (the highest being 6%) [13 && ]. At the time, this six-fold reduction in efficiencies from HSPCs (in vitro) to repopulating HSCs (in vivo) was the gold standard.
Dever et al. [20 && ] published a method that combined HBB-specific Cas9 RNPs (complexed with synthetic modified guide RNAs) with rAAV6 delivery of a HBB homologous donor template to achieve homologous recombination at the b-globin in HSPCs with a GFP/tNGFR reporter, and also to functionally correct the E6V mutation by either point mutation correction or targeted knockin of a HBB cDNA. Consistent with previous reports, there was a 4.5-fold drop from HSPCs prior to transplant (16% GFP þ ) compared with long-term engraftment in the bone marrow (3.5% GFP þ ), but when performing large-scale genome-editing studies with a tNGFR reporter (80 million HSPCs), we observed a smaller reduction (12% in vitro versus 7.5% in vivo), suggesting tNGFR may be a better reporter for optimizing homologous recombination in HSCs at the b-globin locus.
Importantly though, they developed a robust enrichment scheme that purified more than 90% targeted HSPCs early in the culture period that preserved stemness and resulted in a significant increase in the number of targeted human cells in the bone marrow. Interestingly, Agudelo et al. [15 && ], recently published a methodology for marker-free co-selection of homologous recombination at the HBB in cord blood-derived CD34
þ HSPCs by selection of dominant alleles via coediting of the ubiquitous and necessary sodium/potassium pump. It will be necessary to repeat these studies under transplants setting to address whether this enrichment scheme equally purifies HSCs as it does short-lived progenitors. Collectively, these studies hold great promise for Cas9-mediated HBB gene correction in autologous HSCs for the treatment of SCD.
HOMOLOGOUS RECOMBINATION-BASED THERAPEUTIC GENOME EDITING TO RESTORE GENE EXPRESSION AND FUNCTION TO TREAT THE PRIMARY IMMUNODEFICIENCIES
The monogenic primary immunodeficiencies are prime candidates for GE-HSC gene therapy because they can be cured by allo-HSCT whenever a suitable HLA-donor is found and autologous-HSC gene therapy with integrating viral vectors has provided mixed results with insertional mutagenesis being a serious concern for the safety of the patients [36, 37] . One such primary immunodeficiency, X-linked chronic granulomatous disease (X-CGD) is caused by mutations in the CYBB gene that encodes the gp91 phox , which is one of the five components of the NADPH oxidase activity in phagocytes that whenever mutated subsequently results in deadly fungal or bacterial infections [38] . De Ravin et al. [21 & ] used the targeted gene addition strategy to overexpress the CYBB gene via the AAVS1 'safe harbor' site in exon 1 of the PPP1R12C gene in X-CGD patient-derived HSPCs. By making a DSB with AAVS1 ZFNs (delivered as mRNA) while supplying an AAVS1 homologous CYBB donor via rAAV6, they showed functional correction of oxidase activity in X-CGD HSPCs (10-20% of normal HSPCs). It should be noted that they needed the synthetic MND promoter, rather than the endogenous PPP1R12C promoter to obtain robust functional correction and highlights the difficult ability to use the AAVS1 'safe harbor' as a means to drive high-level therapeutic protein expression in HSPCs. Moreover, although the AAVS1 has been asserted to be a safe harbor, the gene encodes for a phosphatase and the long-term safety and efficacy of inserting transgenes into this locus in stem cells has not been determined. These same researchers recently used the point mutation correction strategy to repair the X-CGD C676T disease-causing SNP in X-CGD patient HSPCs using the Cas9/sgRNA system (delivered as RNA) combined with ssODN delivery of the wildtype reversion donor DNA template [16 & ]. Using this strategy, they were able to achieve 12-31% homologous recombination correction (analyzed by NGS of alleles) in vitro and importantly, only saw at most a two-fold reduction in efficiencies in long-term repopulating cells in the bone marrow of NSG mice at 16 weeks posttransplant. Although these in-vivo frequencies are higher than most reports, it is possible that targeting efficiencies in HSCs are locus-dependent. It should also be noted that the researchers reported that whenever increasing the ssODN concentration to 400 mg/ml, they not only saw less targeting efficiencies in vitro (9%), but also reduced frequency in the bone marrow (2%), which highlights the importance of extensive optimization of the ssODN donor molecule. Nonetheless, these results, if repeatable, would be a step in the right direction for the clinical translation of gene editing cell and gene therapies for X-CGD. Although promising, the ssODN strategy is limited in that it can only be applied to specific single point mutations.
IN VIVO HSC GENOME EDITING BY HOMOLOGOUS RECOMBINATION
In vivo HSC gene editing by homologous recombination would be an exciting advancement for hematopoietic gene therapy; although it comes with greater safety risks, such as specificity, immunogenicity, bio distribution and efficacy. Nonetheless, Bahal et al. described an interesting new in-vivo gene editing approach that is independent of engineered nucleases. Researchers injected thalassemic mice with nanoparticles encoding triplex-forming peptide nucleic acids (PNAs) along with homologous donor DNAs that resulted in sustained elevation of hemoglobin levels and up to 7% HBB correction in the bone marrow in vivo [39] . However, it should be noted that this experimental approach required in-vivo delivery of stem cell factor (SCF), which needs to be investigated further to clarify its safety in humans. Although not used to target HSCs in vivo, Suzuki et al. [40] , described a unique methodology for targeted genome editing using Cas9/ sgRNA and homology-independent targeted integration (HiTi) that was shown to target dividing and nondividing cells in the mouse retina. It would very interesting to try this methodology to target quiescent bone marrow-residing HSCs in vivo for homologous recombination.
CONCLUSION
With the first genome editing of autologous HSCs clinical trial being approved by the FDA for the treatment of HIV using ZFNs targeting CCR5 [41 && ], the new paradigm within cell and gene therapy has begun. Now with the variety of genome-editing tools in the toolbox, we can easily typeset the genetic code with base pair precision to reactivate silenced genes through enhancer disruption, replace good genes with bad genes and revert disease-causing nucleotide substitutions, and with that ease of modification, comes great responsibility for all the researchers and clinicians involved. While significant effort needs to be placed on studying hematopoiesis and nuclease off-target activity following HSPC gene editing in rigorous preclinical safety and tumorigenicity models, the history of gene therapy has taught us that preclinical models are incomplete in their ability to fully evaluate an approach and safety and efficacy can only be tested in FDA-approved phase I/II clinical trials. Although the genome-editing studies we describe herein have vastly different strategies for restoring gene function, they all have one thing in common: the development of translational genome-editing research programs that will provide life-long cures for devastating genetic diseases of the blood and the immune systems. This is why we remain optimistic and positive about the future of HSC-focused genome-editing as it will increase the breadth of knowledge of hematopoiesis and stem cell biology that will ultimately help usher in the new era of cell and gene therapies.
